English
简体中文
Total: £ 56.28
Published Date: 2026-02-26 | Pages: 98 | Tables: 98 | New Technology
The global Subcutaneously Injected PD-L1 Antibody market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
PD-L1 antibody is a type of drug in tumor immunotherapy, which reduces immune suppression by binding to PD-L1 and blocking the binding between PD-1 and PD-L1, allowing T cells to exert anticancer effects. At present, PD-L1 antibodies on the market are generally administered intravenously, while subcutaneous injection can avoid various adverse reactions of intravenous infusion and improve patients' medical experience and quality of life.
The North American market for Subcutaneously Injected PD-L1 Antibody is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Subcutaneously Injected PD-L1 Antibody is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Subcutaneously Injected PD-L1 Antibody in Rectal and Renal Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Subcutaneously Injected PD-L1 Antibody include Roche, Alphamab Oncology, Bristol Myers Squibb, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report focuses on the global Subcutaneously Injected PD-L1 Antibody status, future forecast, growth opportunity, key market, and key players. The study objectives are to present the Subcutaneously Injected PD-L1 Antibody development in different regions.
It segments the global Subcutaneously Injected PD-L1 Antibody market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Subcutaneously Injected PD-L1 Antibody manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche
Alphamab Oncology
Bristol Myers Squibb
Segment by Type
Add Hyaluronidase
No Hyaluronidase
Segment by Application
Rectal and Renal Cancer
Lung Cancer
Other
By Region
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Subcutaneously Injected PD-L1 Antibody Market Size Growth Rate by Type (2026-2032)
1.2.2 Add Hyaluronidase
1.2.3 No Hyaluronidase
1.3 Market by Application
1.3.1 Global Subcutaneously Injected PD-L1 Antibody Market Share by Application (2026-2032)
1.3.2 Rectal and Renal Cancer
1.3.3 Lung Cancer
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Subcutaneously Injected PD-L1 Antibody Market Size
2.2 Subcutaneously Injected PD-L1 Antibody Market Size by Region
2.2.1 Subcutaneously Injected PD-L1 Antibody Growth Rate by Region (2026-2032)
2.2.2 Subcutaneously Injected PD-L1 Antibody Market Share by Region (2026-2032)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Use Cases
3 Key Players
3.1 Subcutaneously Injected PD-L1 Antibody Revenue by Players (2026 & 2032)
3.2 Subcutaneously Injected PD-L1 Antibody Key Players Headquarters and Area Served
3.3 Key Players Subcutaneously Injected PD-L1 Antibody Product/Solution/Service
3.4 Date of Enter into Subcutaneously Injected PD-L1 Antibody Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown by Type and Application
4.1 Global Subcutaneously Injected PD-L1 Antibody Market Size by Type (2026-2032)
4.2 Global Subcutaneously Injected PD-L1 Antibody Market Size by Application (2026-2032)
5 North America
5.1 North America Subcutaneously Injected PD-L1 Antibody Market Forecast (2026-2032)
5.2 Subcutaneously Injected PD-L1 Antibody Key Players in North America
5.3 North America Subcutaneously Injected PD-L1 Antibody Market Size by Type
5.4 North America Subcutaneously Injected PD-L1 Antibody Market Size by Application
6 Europe
6.1 Europe Subcutaneously Injected PD-L1 Antibody Market Forecast (2026-2032)
6.2 Subcutaneously Injected PD-L1 Antibody Key Players in Europe
6.3 Europe Subcutaneously Injected PD-L1 Antibody Market Size by Type
6.4 Europe Subcutaneously Injected PD-L1 Antibody Market Size by Application
7 Asia-Pacific
7.1 Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Forecast (2026-2032)
7.2 Subcutaneously Injected PD-L1 Antibody Key Players in Asia-Pacific
7.3 Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size by Type
7.4 Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size by Application
8 Rest of World
8.1 Latin America
8.1.1 Latin America Subcutaneously Injected PD-L1 Antibody Market Analysis
8.1.2 Key Players in Latin America
8.2 Middle East & Africa
8.2.1 Middle East & Africa Subcutaneously Injected PD-L1 Antibody Market Analysis
8.2.2 Key Players in Middle East & Africa
9 International Players Profiles
9.1 Roche
9.1.1 Roche Company Details
9.1.2 Roche Description and Business Overview
9.1.3 Roche Subcutaneously Injected PD-L1 Antibody Introduction
9.1.4 Roche Revenue in Subcutaneously Injected PD-L1 Antibody Business (2026 & 2032)
9.1.5 Roche Recent Development
9.2 Alphamab Oncology
9.2.1 Alphamab Oncology Company Details
9.2.2 Alphamab Oncology Description and Business Overview
9.2.3 Alphamab Oncology Subcutaneously Injected PD-L1 Antibody Introduction
9.2.4 Alphamab Oncology Revenue in Subcutaneously Injected PD-L1 Antibody Business (2026 & 2032)
9.2.5 Alphamab Oncology Recent Development
9.3 Bristol Myers Squibb
9.3.1 Bristol Myers Squibb Company Details
9.3.2 Bristol Myers Squibb Description and Business Overview
9.3.3 Bristol Myers Squibb Subcutaneously Injected PD-L1 Antibody Introduction
9.3.4 Bristol Myers Squibb Revenue in Subcutaneously Injected PD-L1 Antibody Business (2026 & 2032)
9.3.5 Bristol Myers Squibb Recent Development
10 Subcutaneously Injected PD-L1 Antibody Market Dynamics
10.1 Subcutaneously Injected PD-L1 Antibody Industry Trends
10.2 Subcutaneously Injected PD-L1 Antibody Market Drivers
10.3 Subcutaneously Injected PD-L1 Antibody Market Challenges
10.4 Subcutaneously Injected PD-L1 Antibody Market Restraints
11 Key Findings in This Report
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Disclaimer
12.3 Author Details
List of Tables
Table 1. Global Subcutaneously Injected PD-L1 Antibody Market Size Growth Rate by Type (2026-2032) & (US$ Million)
Table 2. Key Players of Add Hyaluronidase
Table 3. Key Players of No Hyaluronidase
Table 4. Global Subcutaneously Injected PD-L1 Antibody Market Size Growth by Application (2026-2032) & (US$ Million)
Table 5. Global Subcutaneously Injected PD-L1 Antibody Market Size by Region (2026-2032) & (US$ Million)
Table 6. Global Subcutaneously Injected PD-L1 Antibody Market Size by Region (2026-2032) & (US$ Million)
Table 7. Global Subcutaneously Injected PD-L1 Antibody Market Share by Region (2026-2032)
Table 8. Market Top Trends
Table 9. Market Use Cases
Table 10. Global Subcutaneously Injected PD-L1 Antibody Revenue by Players (2026 & 2032) & (US$ Million)
Table 11. Global Subcutaneously Injected PD-L1 Antibody Market Share by Players (2026 & 2032)
Table 12. Key Players Headquarters and Area Served
Table 13. Key Players Subcutaneously Injected PD-L1 Antibody Product/Solution/Service
Table 14. Date of Enter into Subcutaneously Injected PD-L1 Antibody Market
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Subcutaneously Injected PD-L1 Antibody Market Size by Type (2026-2032) & (US$ Million)
Table 17. Global Subcutaneously Injected PD-L1 Antibody Market Size Share by Type (2026-2032)
Table 18. Global Subcutaneously Injected PD-L1 Antibody Market Size by Application (2026-2032) & (US$ Million)
Table 19. Global Subcutaneously Injected PD-L1 Antibody Market Size Share by Application (2026-2032)
Table 20. North America Key Players Subcutaneously Injected PD-L1 Antibody Revenue (2026 & 2032) & (US$ Million)
Table 21. North America Key Players Subcutaneously Injected PD-L1 Antibody Market Share (2026 & 2032)
Table 22. North America Subcutaneously Injected PD-L1 Antibody Market Size by Type (2026-2032) & (US$ Million)
Table 23. North America Subcutaneously Injected PD-L1 Antibody Market Share by Type (2026-2032)
Table 24. North America Subcutaneously Injected PD-L1 Antibody Market Size by Application (2026-2032) & (US$ Million)
Table 25. North America Subcutaneously Injected PD-L1 Antibody Market Share by Application (2026-2032)
Table 26. Europe Key Players Subcutaneously Injected PD-L1 Antibody Revenue (2026 & 2032) & (US$ Million)
Table 27. Europe Key Players Subcutaneously Injected PD-L1 Antibody Market Share (2026 & 2032)
Table 28. Europe Subcutaneously Injected PD-L1 Antibody Market Size by Type (2026-2032) & (US$ Million)
Table 29. Europe Subcutaneously Injected PD-L1 Antibody Market Share by Type (2026-2032)
Table 30. Europe Subcutaneously Injected PD-L1 Antibody Market Size by Application (2026-2032) & (US$ Million)
Table 31. Europe Subcutaneously Injected PD-L1 Antibody Market Share by Application (2026-2032)
Table 32. Asia-Pacific Key Players Subcutaneously Injected PD-L1 Antibody Revenue (2026 & 2032) & (US$ Million)
Table 33. Asia-Pacific Key Players Subcutaneously Injected PD-L1 Antibody Market Share (2026 & 2032)
Table 34. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size by Type (2026-2032) & (US$ Million)
Table 35. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Share by Type (2026-2032)
Table 36. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size by Application (2026-2032) & (US$ Million)
Table 37. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Share by Application (2026-2032)
Table 38. Key Players in Latin America
Table 39. Key Players in Middle East & Africa
Table 40. Roche Company Details
Table 41. Roche Description and Business Overview
Table 42. Roche Subcutaneously Injected PD-L1 Antibody Product
Table 43. Roche Revenue in Subcutaneously Injected PD-L1 Antibody Business: 2026 & 2032
Table 44. Roche Recent Development
Table 45. Alphamab Oncology Company Details
Table 46. Alphamab Oncology Description and Business Overview
Table 47. Alphamab Oncology Subcutaneously Injected PD-L1 Antibody Product
Table 48. Alphamab Oncology Revenue in Subcutaneously Injected PD-L1 Antibody Business: 2026 & 2032
Table 49. Alphamab Oncology Recent Development
Table 50. Bristol Myers Squibb Company Details
Table 51. Bristol Myers Squibb Description and Business Overview
Table 52. Bristol Myers Squibb Subcutaneously Injected PD-L1 Antibody Product
Table 53. Bristol Myers Squibb Revenue in Subcutaneously Injected PD-L1 Antibody Business: 2026 & 2032
Table 54. Bristol Myers Squibb Recent Development
Table 55. Subcutaneously Injected PD-L1 Antibody Market Trends
Table 56. Subcutaneously Injected PD-L1 Antibody Market Drivers
Table 57. Subcutaneously Injected PD-L1 Antibody Market Challenges
Table 58. Subcutaneously Injected PD-L1 Antibody Market Restraints
Table 59. Research Programs/Design for This Report
Table 60. Key Data Information from Secondary Sources
Table 61. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Subcutaneously Injected PD-L1 Antibody Market Share by Type in 2026 & 2032
Figure 2. Add Hyaluronidase Features
Figure 3. No Hyaluronidase Features
Figure 4. Global Subcutaneously Injected PD-L1 Antibody Market Share by Application in 2026 & 2032
Figure 5. Rectal and Renal Cancer Case Studies
Figure 6. Lung Cancer Case Studies
Figure 7. Other Case Studies
Figure 8. Subcutaneously Injected PD-L1 Antibody Report Years Considered
Figure 9. Global Subcutaneously Injected PD-L1 Antibody Market Size and Growth Rate 2026-2032 (US$ Million)
Figure 10. Global Subcutaneously Injected PD-L1 Antibody Market Share by Region (2026-2032)
Figure 11. Global Subcutaneously Injected PD-L1 Antibody Market Size Market Share by Type (2026-2032)
Figure 12. North America Subcutaneously Injected PD-L1 Antibody Market Size 2026-2032 (US$ Million)
Figure 13. Europe Subcutaneously Injected PD-L1 Antibody Market Size 2026-2032 (US$ Million)
Figure 14. Asia-Pacific Subcutaneously Injected PD-L1 Antibody Market Size 2026-2032 (US$ Million)
Figure 15. Subcutaneously Injected PD-L1 Antibody Market Size in Latin America (2026-2032) & (US$ Million)
Figure 16. Subcutaneously Injected PD-L1 Antibody Market Size in Middle East & Africa (2026-2032) & (US$ Million)
Figure 17. Bottom-up and Top-down Approaches for This Report
Figure 18. Data Triangulation
Figure 19. Key Executives Interviewed
